{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19075596",
  "DateCompleted": {
    "Year": "2009",
    "Month": "03",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "12",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1873-5576",
      "JournalIssue": {
        "Volume": "8",
        "Issue": "8",
        "PubDate": {
          "Year": "2008",
          "Month": "Dec"
        }
      },
      "Title": "Current cancer drug targets",
      "ISOAbbreviation": "Curr Cancer Drug Targets"
    },
    "ArticleTitle": "The PIK3CA gene as a mutated target for cancer therapy.",
    "Pagination": {
      "StartPage": "733",
      "EndPage": "740",
      "MedlinePgn": "733-40"
    },
    "Abstract": {
      "AbstractText": [
        "The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can be exploited as effective drug targets. Small molecule inhibitors and monoclonal antibodies directed against the protein products of these genetic anomalies have led to cancer therapies with high specificity and relatively low toxicity. Recently, our group and others have demonstrated that somatic mutations in the PIK3CA gene occur at high frequency in breast and other cancers. Moreover, the majority of mutations occur at three hotspots, making these ideal targets for therapeutic development. Here we review the literature on PIK3CA mutations in cancer, as well as existing data on PIK3CA inhibitors and inhibitors of downstream effectors for potential use as targeted cancer therapeutics."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD 21231, USA."
          }
        ],
        "LastName": "Gustin",
        "ForeName": "John P",
        "Initials": "JP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cosgrove",
        "ForeName": "David P",
        "Initials": "DP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Park",
        "ForeName": "Ben Ho",
        "Initials": "BH"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R55 CA109274",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA109274",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "T32 CA009071",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "T32 CA09071",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA109274-04",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "CA109274",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, Non-P.H.S.",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Curr Cancer Drug Targets",
    "NlmUniqueID": "101094211",
    "ISSNLinking": "1568-0096"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Enzyme Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Phosphoinositide-3 Kinase Inhibitors"
    },
    {
      "RegistryNumber": "EC 2.7.-",
      "NameOfSubstance": "Protein Kinases"
    },
    {
      "RegistryNumber": "EC 2.7.1.1",
      "NameOfSubstance": "MTOR protein, human"
    },
    {
      "RegistryNumber": "EC 2.7.1.137",
      "NameOfSubstance": "Class I Phosphatidylinositol 3-Kinases"
    },
    {
      "RegistryNumber": "EC 2.7.1.137",
      "NameOfSubstance": "PIK3CA protein, human"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "Proto-Oncogene Proteins c-akt"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "TOR Serine-Threonine Kinases"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Class I Phosphatidylinositol 3-Kinases"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Enzyme Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Phosphatidylinositol 3-Kinases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phosphoinositide-3 Kinase Inhibitors"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Protein Kinases"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors"
      ],
      "DescriptorName": "Proto-Oncogene Proteins c-akt"
    },
    {
      "QualifierName": [],
      "DescriptorName": "TOR Serine-Threonine Kinases"
    }
  ],
  "CoiStatement": "J.P.G. and D.P.C. declare no conflict of interests. B.H.P. receives support from GlaxoSmithKline under the terms regulated by The Johns Hopkins University policies on conflicts of interest."
}